|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NT5DC2 |
Gene summary for NT5DC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NT5DC2 | Gene ID | 64943 |
| Gene name | 5'-nucleotidase domain containing 2 | |
| Gene Alias | NT5DC2 | |
| Cytomap | 3p21.1 | |
| Gene Type | protein-coding | GO ID | GO:0006793 | UniProtAcc | Q9H857 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64943 | NT5DC2 | C04 | Human | Oral cavity | OSCC | 2.70e-07 | 6.28e-01 | 0.2633 |
| 64943 | NT5DC2 | C21 | Human | Oral cavity | OSCC | 9.72e-08 | 7.56e-01 | 0.2678 |
| 64943 | NT5DC2 | C30 | Human | Oral cavity | OSCC | 1.52e-15 | 1.02e+00 | 0.3055 |
| 64943 | NT5DC2 | C51 | Human | Oral cavity | OSCC | 1.08e-07 | 7.82e-01 | 0.2674 |
| 64943 | NT5DC2 | C08 | Human | Oral cavity | OSCC | 3.70e-08 | 4.26e-01 | 0.1919 |
| 64943 | NT5DC2 | SYSMH3 | Human | Oral cavity | OSCC | 1.06e-20 | 7.21e-01 | 0.2442 |
| 64943 | NT5DC2 | SYSMH5 | Human | Oral cavity | OSCC | 2.97e-05 | 3.63e-01 | 0.0647 |
| 64943 | NT5DC2 | P4_S8_cSCC | Human | Skin | cSCC | 3.93e-02 | 1.40e-01 | -0.3095 |
| 64943 | NT5DC2 | P5_S10_cSCC | Human | Skin | cSCC | 1.95e-09 | 1.95e-01 | -0.299 |
| 64943 | NT5DC2 | P1_cSCC | Human | Skin | cSCC | 1.08e-18 | 5.51e-01 | 0.0292 |
| 64943 | NT5DC2 | P2_cSCC | Human | Skin | cSCC | 3.08e-07 | 2.06e-01 | -0.024 |
| 64943 | NT5DC2 | P4_cSCC | Human | Skin | cSCC | 9.74e-10 | 3.15e-01 | -0.00290000000000005 |
| 64943 | NT5DC2 | P10_cSCC | Human | Skin | cSCC | 5.88e-21 | 4.75e-01 | 0.1017 |
| 64943 | NT5DC2 | male-WTA | Human | Thyroid | PTC | 1.58e-23 | 2.98e-01 | 0.1037 |
| 64943 | NT5DC2 | PTC01 | Human | Thyroid | PTC | 8.86e-07 | 1.40e-01 | 0.1899 |
| 64943 | NT5DC2 | PTC05 | Human | Thyroid | PTC | 3.06e-09 | 3.77e-01 | 0.2065 |
| 64943 | NT5DC2 | PTC06 | Human | Thyroid | PTC | 9.20e-15 | 4.09e-01 | 0.2057 |
| 64943 | NT5DC2 | PTC07 | Human | Thyroid | PTC | 1.59e-26 | 4.47e-01 | 0.2044 |
| 64943 | NT5DC2 | ATC09 | Human | Thyroid | ATC | 2.18e-02 | 1.64e-01 | 0.2871 |
| 64943 | NT5DC2 | ATC12 | Human | Thyroid | ATC | 4.17e-22 | 6.23e-01 | 0.34 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
| GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
| GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
| GO:001631115 | Skin | cSCC | dephosphorylation | 134/4864 | 417/18723 | 2.65e-03 | 1.50e-02 | 134 |
| GO:001631116 | Thyroid | PTC | dephosphorylation | 174/5968 | 417/18723 | 1.20e-05 | 1.31e-04 | 174 |
| GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NT5DC2 | insertion | Frame_Shift_Ins | novel | c.1580_1581insCTGGCTAACACAGCGGGCATGCAGGTGGCAGTGCTGG | p.Pro528TrpfsTer37 | p.P528Wfs*37 | Q9H857 | protein_coding | TCGA-EW-A1P4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | ||
| NT5DC2 | SNV | Missense_Mutation | rs764872514 | c.973C>T | p.Arg325Cys | p.R325C | Q9H857 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| NT5DC2 | SNV | Missense_Mutation | c.307N>A | p.Asp103Asn | p.D103N | Q9H857 | protein_coding | tolerated(0.08) | benign(0.098) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NT5DC2 | SNV | Missense_Mutation | rs748148023 | c.571N>A | p.Glu191Lys | p.E191K | Q9H857 | protein_coding | tolerated(0.05) | benign(0.124) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NT5DC2 | SNV | Missense_Mutation | novel | c.1531N>G | p.Ser511Gly | p.S511G | Q9H857 | protein_coding | tolerated(0.07) | benign(0.062) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NT5DC2 | SNV | Missense_Mutation | novel | c.857N>G | p.Glu286Gly | p.E286G | Q9H857 | protein_coding | tolerated(0.05) | benign(0.021) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| NT5DC2 | SNV | Missense_Mutation | rs185630005 | c.1580N>T | p.Thr527Met | p.T527M | Q9H857 | protein_coding | deleterious(0.02) | possibly_damaging(0.701) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NT5DC2 | SNV | Missense_Mutation | novel | c.1151N>T | p.Glu384Val | p.E384V | Q9H857 | protein_coding | deleterious(0) | benign(0.425) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NT5DC2 | SNV | Missense_Mutation | c.356C>T | p.Ala119Val | p.A119V | Q9H857 | protein_coding | deleterious(0.01) | benign(0.216) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NT5DC2 | SNV | Missense_Mutation | novel | c.969N>A | p.Asp323Glu | p.D323E | Q9H857 | protein_coding | tolerated(0.11) | benign(0.168) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |